pharma news today obesity drugs glp-1 september 2025 Drugmakers are racing to find the next Wegovy. These trials are ones to watch The outlook for obesity from

Incompatible ingredients requiring separation include vitamin C (use morning versus evening rather than together), strong exfoliating acids (alternate nights rather than same routine), and retinoids (can be combined carefully but may increase irritation, alternating nights often works better)

Does anyone in your life have a birthday coming up

For details on how Zepbound compares to other options, see our GLP-1 comparison guides

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardio-vascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Tatschlich enthalten die Produkte nicht deklariertes, in Nahrungsergnzungsmitteln verbotenes, verschreibungspflichtiges Sildenafil und Tadalafil